Glurenorm

Glurenorm is a prescription medication whose active ingredient is gliquidone, a sulfonylurea oral antidiabetic agent. The product is marketed in the European Union, and while the exact tablet strength and dosage form are not specified, it is administered orally to help control blood glucose in adults with type 2 diabetes mellitus. It belongs to the therapeutic class of oral hypoglycemic drugs and works by stimulating insulin release from pancreatic beta‑cells.

Glurenorm (gliquidone) is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan that includes diet and exercise.

- Improves glycemic control by increasing endogenous insulin secretion. - May be prescribed when metformin alone does not achieve target blood glucose levels. - Can be combined with other oral antidiabetic agents such as DPP‑4 inhibitors or SGLT2 inhibitors under medical supervision. - Suitable for patients with preserved pancreatic beta‑cell function. - Used as an adjunct therapy in adults who require additional glucose‑lowering effect.

The safety profile of gliquidone includes a range of observed adverse effects, which are categorized by frequency and clinical significance. Patients should be aware of both common and less frequent but serious reactions.

Common: - Mild hypoglycemia, especially when meals are skipped or delayed. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Skin reactions including rash or pruritus. - Transient elevation of liver enzymes. - Weight gain or increased appetite. - Dizziness or light‑headedness.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions such as angioedema or anaphylaxis. - Hematologic abnormalities like leukopenia or thrombocytopenia. - Acute pancreatitis presenting with abdominal pain and elevated enzymes. - Cardiovascular events such as myocardial infarction or arrhythmia (rare).

When prescribing Glurenorm, clinicians consider several precautionary measures to minimize risk and ensure safe use in diverse patient populations.

- Assess renal and hepatic function before initiation and monitor periodically. - Use caution in elderly patients due to increased susceptibility to hypoglycemia. - Avoid in patients with a history of severe sulfonylurea hypersensitivity. - Adjust dose or discontinue if recurrent hypoglycemic episodes occur. - Counsel patients to maintain regular meal patterns to prevent low blood glucose. - Evaluate for concomitant use of insulin or other secretagogues that may amplify glucose‑lowering effect. - Review pregnancy and lactation status; the safety profile in these conditions is not well established.

Glurenorm may interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events. Understanding these interactions helps clinicians manage therapy safely.

Avoid: - Concomitant use with other sulfonylureas or insulin secretagogues, which can cause profound hypoglycemia. - Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may increase gliquidone plasma levels. - Use with meglitinides (e.g., repaglinide) due to additive insulin‑secretory actions.

Use with caution: - Combination with thiazolidinediones may increase risk of fluid retention and heart failure. - Concurrent use of beta‑blockers can mask hypoglycemia symptoms. - NSAIDs or aspirin may affect renal function, requiring dose adjustment of gliquidone.